Johnson & Johnson said today US regulators rejected its application to market antipsychotic drug Risperdal for patients with autism.
Johnson & Johnson's pharmaceutical research & development unit said given the lack of treatments for autism, it will evaluate the letter and determine the appropriate next steps.
